Trimming the Fat: Acetyl‐CoA Carboxylase Inhibition for the Management of NAFLD

Supported by the American Liver Foundation 2018 Irwin M. Arias, MD Postdoctoral Research Fellowship Award (to N.I.) and NIH grants R37DK048873, R01DK056626, and R01DK103046 (to D.E.C.). SEE ARTICLE ON PAGE 2197 NAFLD is characterized by the hepatic accumulation of excess fatty acids in the form of triglycerides. Normally, the steady‐state concentration of triglycerides in the liver is low. This is because the accrual of fatty acids due to uptake...